Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2026-01-04 @ 4:37 PM
Study NCT ID:
NCT02193893
Status:
UNKNOWN
Last Update Posted:
2014-07-18
First Post:
2014-07-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Biological Treatment of Amyotrophic Lateral Sclerosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000690', 'term': 'Amyotrophic Lateral Sclerosis'}], 'ancestors': [{'id': 'D013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D016472', 'term': 'Motor Neuron Disease'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 50}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ENROLLING_BY_INVITATION', 'startDateStruct': {'date': '2010-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-07', 'completionDateStruct': {'date': '2017-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2014-07-17', 'studyFirstSubmitDate': '2014-07-16', 'studyFirstSubmitQcDate': '2014-07-17', 'lastUpdatePostDateStruct': {'date': '2014-07-18', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2014-07-18', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-07', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety of autologous bone marrow stem/progenitor cell infusion in enrolled patients', 'timeFrame': '1 year', 'description': 'Confirm the safety of autologous bone marrow stem/progenitor cell infusion in enrolled patients by repeated follow-up over one year with clinical and laboratory evaluations.'}], 'secondaryOutcomes': [{'measure': 'Efficacy of autologous bone marrow stem/progenitor cell infusion in enrolled patients.', 'timeFrame': '1 year', 'description': 'Confirm the efficacy of autologous bone marrow stem/progenitor cell infusion in enrolled patients by repeated follow-up over one year with clinical and laboratory evaluation tests for neurodegeneration processes analysis and general health outcomes.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['cell-based therapy', 'autologous bone marrow-derived stem/progenitor cells', 'stem cell infusion, stem cell transplantation', 'biological therapy with neurotrophic factors', 'bioactive neurotrophic factors'], 'conditions': ['Amyotrophic Lateral Sclerosis']}, 'referencesModule': {'references': [{'pmid': '31629403', 'type': 'DERIVED', 'citation': 'Pawlukowska W, Baumert B, Golab-Janowska M, Meller A, Machowska-Sempruch K, Welnicka A, Paczkowska E, Rotter I, Machalinski B, Nowacki P. Comparative assessment and monitoring of deterioration of articulatory organs using subjective and objective tools among patients with amyotrophic lateral sclerosis. BMC Neurol. 2019 Oct 19;19(1):241. doi: 10.1186/s12883-019-1484-2.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells infusion in the subjects with diagnosed amyotrophic lateral sclerosis.', 'detailedDescription': 'Amyotrophic lateral sclerosis (ALS) is a universally fatal neurodegenerative condition that causes weakness leading to paralysis and death. Life expectancy is less that 5 years. The cause is generally unknown and there is no effective treatment. Patients with ALS typically exhibit a progressive paralysis due to the continued loss of motoneurons. Intraspinal injections of bone marrow mononuclear cells have been able to ameliorate the course of ALS in murine models. The purpose of this prospective, nonrandomized, open label, pilot study is to conduct the investigation of the safety and efficacy of infusion of autologous bone marrow-isolated stem/progenitor cells with different selected phenotypes into the subjects with diagnosed ALS. Especially, this clinical trial is designated to test the therapeutic (pro-regenerative and neuro-protective) functions of different stem/progenitor cell populations able to secrete bioactive neurotrophic factors. All patients enrolled will have a documented history of ALS disease prior to study enrollment. Patients diagnosed as early stage of ALS with the duration of disease less than 6 months and patients diagnosed with advanced stage of ALS disease with duration of 6-12 months will be recruited and allocated based on their disease severity to two treatment groups: Group I - patients of early ALS disease stage and Group II - patients of advanced ALS disease. Next, autologous bone marrow-isolated stem/progenitor cells administration to the cerebrospinal fluid at the site of the spinal cord will be performed. Finally, treatment safety, adverse events and exploratory parameters, including electromyographic (EMG) studies, forced vital capacity (FVC), functional rating scale (FRS) and maximum voluntary isometric contraction-arm (MVIC-arm) evaluation, to establish ALS progression rate will be recorded throughout the duration of the post-treatment follow up period.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* diagnosis of the ALS disease before the cell transplantation (diagnose established following the El Escorial criteria for definite ALS)\n* good understanding of the protocol and willingness to consent\n* patient is mentally intact and psychologically stable\n* signed informed consent\n\nExclusion Criteria:\n\nConcomitant of other systemic disease or diseases:\n\n* inflammation (high protein or lymphocytosis in the CSF), active infections.\n* diabetes,\n* cardio-vascular disorders,\n* cancer,\n* autoimmune diseases\n* renal failure,\n* impaired hepatic function.\n* subject is a respiratory dependent.\n* subject unwilling or unable to comply with the requirements of the protocol.\n* patient has been treated previously with any cellular therapy.'}, 'identificationModule': {'nctId': 'NCT02193893', 'acronym': 'NeuStem-ALS', 'briefTitle': 'Biological Treatment of Amyotrophic Lateral Sclerosis', 'organization': {'class': 'OTHER', 'fullName': 'Pomeranian Medical University Szczecin'}, 'officialTitle': 'Safety/Efficacy Study for the Biological Treatment of Amyotrophic Lateral Sclerosis With Autologous Stem/Progenitor Cells', 'orgStudyIdInfo': {'id': 'ZPO 02'}, 'secondaryIdInfos': [{'id': 'ZPO 02, ALS-BMSC #01', 'type': 'OTHER', 'domain': 'Department of General Pathology, PMU in Szczecin'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Stem/progenitor cells transplantation.', 'description': 'Intervention: Biological: Cell-based therapeutics Autologous bone marrow-derived stem/progenitor cells will be transplanted intrathecally (via a standard lumbar puncture) into early vs. progressive ALS subjects.', 'interventionNames': ['Other: Biological: Cell-based therapeutics']}, {'type': 'SHAM_COMPARATOR', 'label': 'Standard treatment of ALS', 'description': 'Symptomatic treatment of ALS without biologic cell-based treatment', 'interventionNames': ['Other: Symptomatic treatment of ALS']}], 'interventions': [{'name': 'Biological: Cell-based therapeutics', 'type': 'OTHER', 'description': 'Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.', 'armGroupLabels': ['Stem/progenitor cells transplantation.']}, {'name': 'Symptomatic treatment of ALS', 'type': 'OTHER', 'description': 'Symptomatic neurological treatment of ALS', 'armGroupLabels': ['Standard treatment of ALS']}]}, 'contactsLocationsModule': {'locations': [{'zip': '71-252', 'city': 'Szczecin', 'state': 'Poland', 'country': 'Poland', 'facility': 'Department of Neurology of Pomeranian Medical University in Szczecin', 'geoPoint': {'lat': 53.42894, 'lon': 14.55302}}], 'overallOfficials': [{'name': 'Boguslaw Machalinski, MD, PhD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pomeranian Medical University Szczecin'}, {'name': 'Przemyslaw Nowacki, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Pomeranian Medical University Szczecin'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pomeranian Medical University Szczecin', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator: Boguslaw Machalinski, Professor and Chief, Department of General Pathology, Pomeranian Medical University, Pomeranian Medical University Szczecin', 'investigatorFullName': 'Milosz Kawa', 'investigatorAffiliation': 'Pomeranian Medical University Szczecin'}}}}